When Bemis Healthcare Packaging (BHP) first introduced its CXB product line to the marketplace, the resin composition of the sealant technology was kept confidential while awaiting publication of a corresponding patent application.
“Now that our patent application has published, Bemis Healthcare Packaging is pleased to let the industry know that the commercial version of this sealant utilizes TOPAS cyclic olefin copolymer (COC) resin,” says Georgia Mohr, BHP’s Marketing Director for Pharmaceuticals. “We originally developed the CXB sealant to compete against Barex sealant. So, when INEOS announced the discontinuation of Barex production, BHP was already prepared to bring solutions to its customers to help ease the transition. Customers immediately responded to the fact that BHP’s CXB sealant offers similar properties to polyacrylonitrile (Barex) when it comes to low drug uptake, barrier properties, and high chemical resistance.”
CXB is today the preeminent sealant for transdermal patch and oral strip packaging. Finding the right combination of packaging resins to protect the active pharmaceutical ingredient (API) and the excipient is no guessing matter. The science behind BHP’s proprietary CXB sealant is the product of years of research and long hours in the lab. BHP internal testing has consistently shown that our CXB sealant has superior barrier and permeation performance (similar to that of Barex sealant), particularly for nicotine and other APIs commonly used in transdermal patch and oral strip applications.
CXB sealant is part of a suite of sealants BHP offers for transdermal and oral strip applications. Other sealant solutions include sealants based on PE, PET, and Surlyn resins.
